All In Biotech

NDA 018892 · Hospira

Sodium Phosphates In Plastic Container

Sodium Phosphate, Dibasic, Heptahydrate, Sodium Phosphate, Monobasic, Monohydrate · Intravenous

Last checked: Nov 20, 2026Latest source record: Nov 30, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1983

May 10, 1983

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2

0 Phase 3, 0 recruiting

FAERS reports

214

197 serious, 51 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 12, 2026.

INDICATIONS AND USAGE Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 10, 1983 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
  • SODIUM PHOSPHATES IN PLASTIC CONTAINER · SODIUM PHOSPHATE, DIBASIC, HEPTAHYDRATE 4.02GM/15ML; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE 4.14GM/15ML (268MG/ML · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Sodium Phosphates In Plastic Container" as an intervention, any sponsor and status, largest first.

All 2 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • asthenia19
  • diarrhoea19
  • renal failure acute19
  • nausea18
  • constipation16
  • dehydration14
  • fall14
  • pyrexia14
  • vomiting14
  • dizziness13
  • dyspnoea13
  • urinary tract infection13

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
20052
200622
200719
200821
200928
201023
201114
201216
20131
20151
20163
20174
20187
20191
20203
20216
202210
20235
20249
20259
20268

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Pfizer

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.